Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Quarterly EPS Estimate At $-1.71

0

The EPS estimate of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for quarter completed 2017-03-31 is $-1.71.

The EPS predictions registered a week and month ago were $-1.71 and $-1.71 correspondingly. EPS estimates registered in preceding 60 and 90 days were $-1.71 and $-1.71 correspondingly. The variance in EPS predictions over previous week is 0%.

The count of EPS reviews negative and up over previous week was 0 and 0, correspondingly. The affirmative EPS review in the prior 30 and 60 days were 1, and 1, however, for 90 and 120 days were 1 and 0.

The EPS negative assessments in the last 30 and 60 days was 3, and 3, though in, 90 and 120 days was 2 and 1.

The positive and negative review of per-share earnings in the earlier 18 days were 0 and 0 correspondingly.

Earnings Surprises

The mean EPS approximation previous to the financial report statement for the period closed 3 is $-1.71 calculated as per 12 EPS predictions. The financial account performance was released on 2016-11-07 and EPS was $-1.64. The surprise count was $-0.08 per share and seen in fraction, it was -5.13%. The standard deviation of given EPS prior to release is $0.06.

Quarterly Sales Estimates

The mean of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) annual sales estimates is $2.09 and the median of sales predictions is $2.09. The estimate is computed by 2 analysts for the fiscal 2017.

The highest yearly prediction is $2.2 and the lowest estimate is $1.98. Annual sales estimates demonstrate standard deviation of $0.155.

The number of analysts reviewing the equity and folks who have abridged and upped sales prediction in the prior week are 2 and 2 correspondingly. The modification in the mean prediction is 0%.

The analysts casing the security and those who have lowered and upped prediction for sales in the prior month are 2 and 2 correspondingly. From last month, the alteration in the mean estimate is -75.136%.

The analysts count after the stock and those who have lowered and upped estimate for sales in the former quarter are 2 and 2 respectively. From earlier quarter, the alteration in the mean estimate is -75.136%.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 8 times, 1 visits today)